Pfizer Announced That Based On Results From The Ongoing Pharmacokinetic Study, The Company Has Selected Its Preferred Once-daily Modified Release Formulation For Danuglipron. Pfizer Plans To Conduct Dose Optimization Studies In The Second Half Of 2024
Pfizer Announced That Based On Results From The Ongoing Pharmacokinetic Study, The Company Has Selected Its Preferred Once-daily Modified Release Formulation For Danuglipron. Pfizer Plans To Conduct Dose Optimization Studies In The Second Half Of 2024
輝瑞宣佈，根據正在進行的藥代動力學研究的結果，該公司已爲Danuglipron選擇了其首選的每日一次的改性釋放配方。輝瑞計劃在2024年下半年進行劑量優化研究
Pfizer Announced That Based On Results From The Ongoing Pharmacokinetic Study, The Company Has Selected Its Preferred Once-daily Modified Release Formulation For Danuglipron. Pfizer Plans To Conduct Dose Optimization Studies In The Second Half Of 2024
輝瑞宣佈，根據正在進行的藥代動力學研究的結果，該公司已爲Danuglipron選擇了其首選的每日一次的改性釋放配方。輝瑞計劃在2024年下半年進行劑量優化研究
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。